Profound Medical opened lower at $7.72, compared with its previous close of $7.85. In the last trading session, the stock traded between $7.36 and $7.92. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Profound Medical is now worth
$ 62.44
Resulting in a loss of
$ 37.56 (37.56%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.43 (-5.43%)
Day High
$7.92
Day Low
$7.36
Day Open
$7.72
Prev Close
$7.85
Volume
1,29,790
1W Return
3.99%
1M Return
2.16%
3M Return
6.13%
6M Return
2.40%
1Y Return
15.55%
Market Cap ($ Mn)
272
PE Ratio
-
PB Ratio
5.02
PEG Ratio
-
ROE
-85.47%
ROCE
-81.27%
EPS (TTM)
$-0.26
1 Week
3.99%
1 Month
2.16%
3 Months
6.13%
6 Months
2.40%
9 Months
15.28%
Profound Medical taps Montel Williams for prostate care webinar
Montel Williams joins Profound Medical's 'Let's Huddle' webinar on November 5, 2026. Event focuses on prostate care, health advocacy, and patient support. Profound Medical installed first TULSA-PRO system at a VA facility for veterans. Webinar hosted by Leonard Wheeler, former NFL player and patient ambassador.
21 days agoProfound Medical signs co-education pact with Telix Pharmaceuticals
Profound Medical and Telix Pharmaceuticals enter co-education agreement to integrate PSMA-PET imaging with TULSA-PRO therapy. Collaboration aims to expand TULSA-PRO’s addressable market by improving patient selection through precise diagnostic imaging. Profound is developing PSMA-PET–MR image-fusion capabilities for its Treatment Delivery Console software. Agreement includes joint educational initiatives such as scientific meetings, webinars, and clinical case studies.
1mo agoProfound Medical appoints Richard Fabian as president
Richard Fabian appointed as President of Profound Medical Corp. Appointment effective immediately. Mathieu Burtnyk shifts to Chief Technology Officer role. Company focuses on interventional MRI procedures.
2mo agoProfound Medical promotes Sobczyk to interim CFO
Profound Medical Corp appoints Matthew Sobczyk as interim CFO, replacing Rashed Dewan. Sobczyk joins from within as Corporate Controller, bringing deep institutional knowledge since joining in 2020. Dewan will stay on a short-term consulting basis to aid the transition. The leadership change occurs as Profound continues to commercialize its TULSA-PRO and Sonalleve platforms globally.
3mo agoProfound Medical launches Let's Huddle for prostate patient support
Profound Medical Corp. introduced Let's Huddle, a global support community for prostate cancer patients led by ambassador Leonard Wheeler. The initiative complements the company's TULSA-PRO® and Sonalleve® technologies by focusing on patient education and peer support throughout the care continuum.
3mo agoProfound Medical affirms $25.000M FY26 sales outlook vs estimate
Profound Medical has reaffirmed its full-year 2026 sales guidance of $25.000 million, continuing to fall short of the $26.858 million analyst estimate. This update confirms the company's current financial trajectory despite the divergence from market expectations.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Profound Medical is now worth
$ 62.44
Resulting in a loss of
$ 37.56 (37.56%)
Note: Past profits do not guarantee future returns.
